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ABSTRACT
OBJECTIVE: To determine if Alitretinoin is a safe and effective alternative to current treatments
in reducing the symptoms of Hand Eczema (HE)
STUDY DESIGN: Review of all English language primary double-blind randomized controlled
trial studies and an exploratory open-label case series from 1999-2009
DATA SOURCES: An exploratory open-label case series comparing Alitretinoin at various
dosages and randomized, controlled, double-blind clinical trials comparing Alitretinoin to
placebo. All sources were found using PubMed and Cochrane databases.
OUTCOME MEASURED: The open-label case series was a pilot study where the treating
physician measured erythema, papules/vesicles, desquamation, hyperkeratosis, rhagades and
pruritus/pain on a 4-point scale from 0(no symptoms) to 4(severe symptoms). Participants were
evaluated monthly for 1-5 months, depending on how well each participant tolerated treatment.
The randomized, controlled, double-blind clinical trials measured the modified Total Lesion
Symptom Score (mTLSS), which measured the intensity of seven individual symptoms of
chronic hand eczema: erythema, scaling, lichenification/hyperkeratosis, vesiculation, oedema,
fissures, and pruritis/pain. Participants of these studies were evaluated for each symptom with a
score of 0(no signs or symptoms) to 3(severe symptoms) at baseline, twelve weeks, and twentyfour weeks.
RESULTS: The open-label case series by Bollag found oral Alitretinoin to be very efficacious
in the treatment of HE. The two double-blind randomized controlled trials, by Ruzicka and
Bissonnette, indicate significant results using oral Alitretinoin. Results showed Alitretinoin
induces clinically significant responses in a high percentage of patients with severe chronic hand
eczema as both initial treatment as well as subsequent treatment for HE refractory to initial
treatment with Alitretinoin. Participants in all studies experienced only mild side effects from
treatment, the most common of which was headache.
CONCLUSIONS: The results of these studies show that use of oral Alitretinoin given at
individually well-tolerated doses (30-40 mg) induces clearing of HE in a substantial proportion
of patients with severe disease refractory to standard corticosteroid therapy as well as HE
refractory to treatment with a previous course of Alitretinoin. Additionally, these studies show
that Alitretinoin can be used safely as intermittent treatment for long-term management of HE.
KEY WORDS: Alitretinoin, Hand Eczema
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INTRODUCITON
Hand eczema (HE) is the most common dermatosis that affects the hands and many
patients suffer from the condition chronically despite avoidance of causative agent(s). The
current treatment for HE is long-term use of topical corticosteroids. However, even with this
treatment patients experience decreased response over time, rebound flares, and overall lack of
improvement.1 This paper evaluates two randomized controlled clinical trials that compare
doses of 10 mg and 30 mg oral treatments of Alitretinoin to placebo. Additionally evaluated is
one open-label case series which compares multiple dosing regimens and tapers. All studies
were conducted in an effort to decrease symptoms of patients suffering from HE and improve
long-term management.
HE affects 7-12% of the general population of Northern Europe and is estimated to affect
an even higher percentage of the population in the United States. Of the patients diagnosed with
HE, 5-7% of them usually develop chronic hand eczema (CHE). There are many irritants,
allergens, and exogenous factors that exacerbate HE, making it difficult to identify all triggers of
the dermatosis. In severe cases, HE can cause occupational disability if the use of hands plays a
key role in performing a job. HE can also cause psycho-social disability as the condition can
cause substantial disfiguring of the hands.2 In the Netherlands, annual costs of medical care,
absenteeism, and disability pensions due to occupational skin disease in employees in 2001 were
estimated at € 98.1 million (equivalent = $132 million). There are currently no estimates for the
number of healthcare visits per year for HE.1-3
A specific cause of HE is unknown but it is hypothesized to be multifactorial. This
condition is characterized by pruritis, which leads to erythema, vesiculation, scaling,
lichenification, hyperkeratosis, blistering, fissures, and pain. The long-term prognosis is
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poor. Current therapies include skin protection practices (i.e. gloves), lifestyle changes to avoid
irritants, use of emollients, and topical corticosteroids. Despite these treatments, many patients
suffer chronically. Because the efficacy of topical corticosteroids tends to decline over time,
there is a great push to find a treatment that has consistent results with long-term use. Retinoids
are known to affect keratinization & inflammation. Alitretinoin is a retinoid that binds to all six
retinoid receptors in contrast to tretinoin, acitretin, and retinoic acid which have less binding
capacity. Previous studies have shown topical Alitretinoin (Panretin®) to be beneficial for AIDS
patients with skin lesions from Kaposi sarcoma. Current research is hopeful that Alitretinoin
will have a similar beneficial effect on the skin for individuals suffering from HE.1,4,5
OBJECTIVE:
The objective of this systematic review is to determine whether or not "Is Alitretinoin (9cis-retinoic acid) safe & effective for use in Hand Eczema?” The hypothesis about the objective
is that Alitretinoin given at well-tolerated doses is effective and an acceptable long-term
treatment in clearing HE in patients with severe disease refractory to standard corticosteroid
therapy.
METHODS:
A detailed search was completed by the author, using search engines PubMed and
Cochrane Database of Systematic Reviews. The key words “Alitretinoin” and “Hand Eczema”
were used in combination to search for English articles and all of the resulting articles were
published in peer-review journals from 1999-2009. The articles were selected based on the
importance of outcomes to patient (Patient Oriented Evidence that Matters, or POEMS). Studies
that were included were those that were randomized, controlled, prospective, and were based on
a patient-oriented outcome. Excluded studies were those that used Alitretinoin as treatment for
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diseases other than HE. Randomized controlled trials (RCTs) were searched for those with a
patient population between 16 and 75 y.o. with clinically diagnosed HE that was refractory to
standard corticosteroid treatment. Only RCTs that compared treatment groups receiving oral
Alitretinoin compared to a placebo group were considered. In addition, one exploratory openlabel case series compared multiple dosing regimens of Alitretinoin for tolerance and
effectiveness.5 Under these criteria, two double-blind, randomized, placebo-controlled clinical
trials and one open-label case series were identified and are included in this review. Table 1
includes demographics of the included studies. The two RCT studies reported statistics based on
numerical severity scores of CHE symptoms. Statistics reported or used include p-values with a
value of <0.05 being statistically significant. 1-2,5
OUTCOMES MEASURED
Outcomes of the studies by Ruzicka and Bissonnette were measured by severity
categorization, which corresponded to the intensity of HE symptoms. Severity was defined
according to the Physician Global Assessment (PGA) whereby seven symptoms are evaluated
using the modified Total Lesion Symptom Score (mTLSS). The mTLSS addressed erythema,
scaling, lichenification/hyperkeratosis, vesiculation, edema, fissures, and pruritis/pain. PGA
categories were based on the mTLSS and ranged from “clear” to “severe.” Among the seven
total symptoms being addressed, qualifications were as follows: Clear- no symptoms;
undetectable, Almost Clear- at least one mild symptom/absent affecting <10% of hand surface,
Mild- at least one mild symptom affecting <10% of hand surface, Moderate- at least one mild or
moderate symptom affecting 10-30% of hand surface, Severe- at least one moderate or severe
symptom affecting >30% of hand surface. Participants were given a score for each of the seven
symptoms that, when added together, determined the PGA score. The scoring for each of the
mTLSS symptoms rated on a scale from 0-3 where 0= no symptoms, 1=mild, 2=moderate, and
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3=severe symptoms. The criteria for the scoring of each symptom is as follows: Erythema 0absent, 1- faint, 2-prominent redness, 3-deep intense red color, Scaling 0-absent, 1- slight flaking
over limited areas/mostly fine scales, 2- flaking over widespreasd areas(s)/coarser scales, 3desquamation covering over 30% of hand with coarse thick scales, Lichenification/
Hyperkeratosis 0- absent, 1- mild thickening with exaggerated skin lines over limited areas, 2palpable thickening over widespread areas, 3- prominent thickening over widespread areas with
exaggeration of normal skin markings, Vesiculation 0- absent, 1- scattered vesicles affecting up
to 10% of hand without erosion, 2- scattered or clustered vesicles affecting up to 30% of hand
without erosion or excoriation, 3- high density of vesicles extending over large areas(s), or with
erosion or excoriation, Edema 0- absent, 1- dermal swelling over less than 10% of hands, 2definite dermal swelling over more than 10% of hand, 3- dermal swelling with skin induration
over widespread areas(s), Fissures 0- absent, 1- cracked skin affecting a small area of the hand,
cracked skin affecting multiple areas of the hand & causing pain, 3- one or more deep fissures
and causing bleeding or severe pain, Pruritus/Pain 0- absent, 1- occasional, slight discomfort a
few times per day, 2- intermittent, causing discomfort frequently during the day, 3- persistent or
interfering with sleep.1-2
Bollag evaluated slightly different CHE symptoms: erythema, papules/vesicles,
desquamation, hyperkeratosis, rhagades, and pruritus/pain, which were rated on a 0-4 point scale
where 0- none, 1- slight, 2-moderate, 3-marked, 4-severe. These scores were based on a
subjective assessment by the treating physician on the correlation between Therapeutic Response
(TR) and the Reduction of the Total Lesion/Symptom Score (rTLSS). The rTLSS was recorded
as a percentage that corresponded to a categorization of TR such that 0-20%- no therapeutic
response, 21-40%- slight response, 41-60%- moderate response, 61-80%- good response, 81100%- very good response.5
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Table 1. Characteristics of studies included in systematic review of the safety & effectiveness of
Alitretinoin (9-cis-retinoic acid) for use in Hand Eczema
Study

Type

#Pts

Age Inclusion
(yrs) Criteria

Bissonnette,
CANADA
2009

Doubleblind,
placebo
controlled,
RCT

117

4952

38

Bollag,
Open label,
SWITZERLAND Case Series
1999

Ruzicka,
GERMANY
2008

Double1032
blind,
placebo
controlled,
prospective,
multicentre
RCT

Exclusion
Criteria

W/
D

Interventi
ons

BACH
participants
who rated as
“clear” or
“almost clear”
hands
according to
PGA at
termination of
treatment, but
then relapsed
within 24
weeks

immunosuppressants
used within last 4
weeks
drugs with potential
interactions (i.e.
systemic azoles,
erythromycin,
clarithromycin,
simvastatin, St.
John’s wort) within
last 2 weeks,
use of concomitant
retinoids (oral or
topical to hands),
vitamin supplements
with > 2000 IU Vit.
A

24

Alitretinoin
10 mg or 30
mg po QD x
12-24 weeks

1685

Patients with
CHE
refractory to
conventional
therapy;
emphasis on
hyperkeratotic
palmar
eczema

N/A

0

Alitretinoin
20 mg or 40
mg po x 1-5
months

1875

18-75 y.o. and
diagnosed
with any type
of severe hand
eczema
(CHE) of at
least 6 months
refractory to
standard
topical
corticosteroid
therapy

Diagnosis of
psoriasis, atopic
dermatitis treated
with prescription
drugs, active
bacterial/fungal/viral
infection of hands,
or allergic contact
dermatitis of hands
with unavoidable
exposure to allergen,
or other skin
diseases likely to
interfere with the
study
Use of concomitant
retinoids (oral or
topical to hands),
vitamin supplements
with > 2000 IU
Vitamin A

273 Alitretinoin
10 mg or 30
mg po QD x
up to 24
weeks
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RESULTS
This review includes double-blind, prospective, and exploratory open label studies
analyzed with intention to treat with study participants being diagnosed with HE based on
clinical criteria. In the Bissonnette and Ruzicka studies, participants receiving Alitretinoin
received 30 mg or 10 mg tablets by mouth while participants in the Bollag study received 20-40
mg soft gelatin capsules of Alitretinoin by mouth.1-2,5 The Ruzicka study had the most
participants with 409, 418, and 205 participants assigned to the 30 mg, 10 mg, and placebo
groups respectively. 276 participants left the study due to insufficient response or adverse
effects. Therefore, 759 participants finished the study with 303 in the 30 mg goup, 319 in the 10
mg group, and 137 in the placebo group.2 The Bissonnette study had the next greatest number of
participants with 49, 21, and 47 in the 30 mg, 10 mg, and placebo groups respectively. 24
participants were withdrawn due to adverse effects.1 The Bollag study had the least number of
total participants with 38 entering and 38 completing the study.5
In the studies by Ruzicka and Bissonnette, participants were evaluated with mTLSS and
PGA scores at baseline. Participants were reevaluated at 12 and 24 weeks. Assessment was
carried out based on severity symptoms of each case of HE. Symptoms tested consisted of
erythema, scaling, lichenification/hyperkeratosis, vesiculation, edema, fissures, and pruritus/pain.
Each symptom was rated on a scale from 0(absent symptoms) to 3(severe symptoms) with 21
being the maximum number of points possible.1-2 The Bollag study evaluated symptoms of
erythema, papules/vesicles, desquamation, hyperkeratosis, rhagades, and pruritus/pain.
Symptoms were recorded as rTLSS on a scale from 0(absent symptoms) to 4(severe symptoms)
for a maximum score of 24.5 The TLSS was converted to a percentage of participants who had
improvement of symptoms (reduction in TLSS scores) from baseline scores for oral Alitretinoin
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groups vs. placebo as shown in Table 2.
Table 2. Median Percent Reduction in Total Lesion Symptom Score (mTLSS or rTLSS)
from Baseline at each evaluation period for patients treated with oral Alitretinoin vs.
Placebo for Symptoms of Hand Eczema
Study

Therapy

Ruzicka

30 mg oral Alitretinoin
10 mg oral Alitretinoin
Placebo
30 mg oral Alitretinoin
10 mg oral Alitretinoin
Placebo

Bissonnette

Bollag

20 or 40 mg oral Alitretinoin**

Time
12 weeks
*
*
*
81.3
53.9
33.4
16 weeks
86.0

24 weeks
75.0
56.0
39.0
92.4
70.9
42.9

*mTLSS scores not reported. If, at 12 weeks, participant had a mTLSS resulting in a PGA of
“clear” or “almost clear,” treatment was discontinued. Remaining participants were evaluated at
24 weeks.2
**27 participants received 40 mg for entire treatment period; 3 participants took 40 mg for 1
month and then 20 mg for the remainder of the study due to adverse effects; 8 participants began
on 20 mg, 5 of whom continued this dose while 3 had dose increased to 40 mg after 1 month due
to minimal response.5
As shown in Table 2, percentage reduction of symptoms from baseline to the end of the studies
proved to be substantial over all groups. In the Ruzicka and Bissonnette studies, participants
treated with 30 mg oral Alitreatinoin showed both early and clinically significant responses to
treatment as compared to the 10 mg and placebo groups. The slightly decreased percentage of
the TLSS in the 10 mg oral Alitretinoin group shows that treatment success is greater at higher
doses. Additionally, both of these studies showed statistically significant decreases in TLSS
among groups treated with 30 mg oral Alitretinoin with p-values of p<0.001.1-2 P-values were
not reported for the Bollag study though the majority of participants (86%) had very successful
responses to treatment.5
In order to analyze results, studies with “continuous” data were converted to
“dichotomous” data. This was the case for the Bollag study. It was decided that participants
with “Good” to “Very Good” improvement of symptoms would be considered significant change
and that participants with “None, Slight, or Moderate” improvement would be considered
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insignificant change. In this way, the “experimental event rate” (EER) was determined as the
percentage of participants who experienced “Good” or “Very Good “ improvement with 9-cisretinoic acid (RA). The “control event rate” (CER) was determined to be the percentage of
“Good or “Very Good” improvement with retinoids other than 9-cis-RA. As for the studies by
Ruzicka and Bissonnette, data was dichotomous already and therefore required no conversion.1-2
Using these numbers, a Relative Benefit Increase (RBI) and an Absolute Benefit Increase (ABI)
could be calculated. The Numbers Needed to Treat (NNT) of patients who needed to use
Alitretinoin to improve their HE was determined from the ABI by subtracting the CER from the
EER, and using the inverse result of 1/ABI. The calculated analysis of outcomes and NNT in
order to decrease the severity score of patients treated with oral Alitretinoin vs. placebo for HE
can be seen in Table 3.
Table 3. Analysis of Outcomes and NNT in Order to Decrease the Severity Score of
Patients Treated with Alitretinoin for HE
Study
Ruzicka
Bissonnette
30 mg dose
10 mg dose
Bollag

# completed
study
759
93

38

CER(%)

EER(%)

RBI(%)

ABI(%)

NNT(%)

p value

17

48

182

31

4

<0.001

8
10
5

80
48
89

900
380
1680

72
38
84

2
3
2

<0.001
<0.004
N/A

As can be seen in Table 3, the RBI was substantial in all three studies with the Bollag
study showing, by far, the highest percent increase. Despite the relatively large differences in
RBI among the three studies, the NNT were quite similar, ranging from 2-4 patients.
In each of the studies, participants complained of a few adverse effects to treatment,
likely associated with hypervitaminosis A syndrome. The symptoms associated with this
syndrome are headache, flush, conjunctivitis, mucocutaneous manifestations (chilitis, dry skin,
dry lips), and musculoskeletal symptoms. Adverse effects were found to be dose dependent.1-2,5
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In the Ruzicka study, 276 participants left the study due to insufficient response or adverse
effects while the Bissonnette study had 24 withdraw due to adverse effects.1-2 All participants
that began the Bollag study completed it by decreasing Alitretinoin dose if patients experienced
adverse effects or increasing the dose if patient showed signs of insufficient response.5
DISCUSSION
The Randomized Controlled Trials and Open-Label Case Series in this review of the
safety and efficacy of oral Alitretinoin in the treatment of HE showed that the medication can
safely and effectively treat symptoms of the condition when given at maximal tolerated doses
without causing adverse effects (30-40 mg). Perhaps the Bollag study was most successful with
highest RBI and lowest NNT because the study design allowed augmentation of the Alitretinoin
depending on an individual’s response to a particular dose. In this way, though doses varied, all
participants were able to be treated until a successful outcome was reached.
Alitretinoin gel (Panretin®) was initially approved in the U.S. as topical treatment for
AIDS-related Kaposi’s Sarcoma. A current off-label use is for treatment of T-cell lymphoma. It
was not until August 2008 that Swiss manufacturer Basilea Pharmaceutica got approval to use
their product Toctino®, an oral Alitretinoin, for treatment of HE. Since then, it has been
approved in other countries, including U.S., for HE treatment. However, in 2010, the National
Institute for Health and Clinical Excellence (NICE) made a recommendation that Toctino® be
started only in patients severely affected by HE, and be discontinued as soon as adequate
response is observed, or if HE remains severe for 12 weeks, or if inadequate response at 24
weeks. Effects of long-term use are unknown. 6
The studies evaluated by this paper were limited by the novelty of Alitretinoin as a
treatment for HE. Though it has approved uses for other medical conditions, Alitretinoin is a
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fairly new drug overall. Literature on oral Alitretinoin is scarce. To date, no research about oral
Alitretinoin has been published in U.S. Current publications are essentially pilot studies and are
broadly directed. As more is learned about the drug and its long-term effects, studies will be
able to be more specifically structured.
CONCLUSION
Alitretinoin is an effective treatment for HE when the condition is refractory or
unresponsive to corticosteroid therapy. The studies presented here show no severe adverse
effects with use of Alitretinoin for up to a year, however, based on the most current literature and
NIH recommendation, it is suspected that Alitretinoin may not be safe to use as long-term
treatment for HE. Until the safety and efficacy of oral Alitretinoin can be definitively
determined in a long-term trial, future research could be directed at determining more
specifically the triggering agents that exacerbate HE. In this way, individuals who suffer from
HE could be treated in a more preventative manner. Avoiding triggers would likely prove to be
safe practice and may very well be more effective than use of a long-term topical agent.
If future studies prove to be as successful as those already completed, researchers will likely
continue to get the funding they need to further explore this drug which holds much promise for
the many sufferers of this physically painful, emotionally frustrating, and economically
consuming chronic condition.
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